

## New Hampshire Medicaid Fee-for-Service Program Fibromyalgia Criteria

Approval Date: December 3, 2019

### Medications

Brand Name	Generic Name	Dosage Strengths
Savella®	milnacipran	12.5 mg, 25 mg, 50 mg, 100 mg tablets, 4-week titration pack

For requests for duloxetine (Cymbalta®) use the Cymbalta® criteria

For requests for pregabalin (Lyrica® and Lyrica® CR) use the Lyrica® criteria

### Criteria for Approval

1. Diagnosis of Fibromyalgia; **AND**
2. Physical Fitness Intervention (e.g., physical therapy, exercise); **AND**
3. Trial and failure of, or contraindication to, treatment with one of the following two:
  - a. Amitriptyline 50 mg daily; **OR**
  - b. Cyclobenzaprine 30 mg daily; **AND**
4. No concurrent therapy of these medications (duloxetine, pregabalin, milnacipran) beyond 30 days.

### Criteria for Denial

1. Criteria for approval not met.

**Length of Authorization:** One year

### Criteria for Denial

1. Criteria for approval not met.

### References

Available upon request.

Proprietary & Confidential

© 2006–2019 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

## Revision History

Reviewed by	Reason for Review	Date
Pharmacy & Therapeutic Committee	Update	09/05/2006
Commissioner	Approval	09/29/2006
Pharmacy & Therapeutic Committee	Update	11/06/2008
Commissioner	Approval	12/01/2008
DUR Board	Revision	03/22/2010
Commissioner	Approval	04/30/2010
DUR Board	Revision	06/22/2010
Commissioner	Approval	08/03/2010
DUR Board	Revision	10/19/2011
Commissioner	Approval	04/12/2012
DUR Board	Revision	10/11/2016
Commissioner	Approval	11/22/2016
DUR Board	Revision	09/27/2018
Commissioner Designee	Approval	11/27/2018
DUR Board	Revision	10/28/2019
Commissioner Designee	Approval	12/03/2019